Copyright Reports & Markets. All rights reserved.

Global Liposomes Nanoparticle Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Liposomes Nanoparticle Drugs by Type
    • 1.3.1 Overview: Global Liposomes Nanoparticle Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Liposomes Nanoparticle Drugs Consumption Value Market Share by Type in 2025
    • 1.3.3 Liposomes Drugs
    • 1.3.4 Lipid Nanoparticle Drugs
  • 1.4 Global Liposomes Nanoparticle Drugs Market by Application
    • 1.4.1 Overview: Global Liposomes Nanoparticle Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Retail Pharmacy
    • 1.4.4 Other
  • 1.5 Global Liposomes Nanoparticle Drugs Market Size & Forecast
  • 1.6 Global Liposomes Nanoparticle Drugs Market Size and Forecast by Region
    • 1.6.1 Global Liposomes Nanoparticle Drugs Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Liposomes Nanoparticle Drugs Market Size by Region, (2021-2032)
    • 1.6.3 North America Liposomes Nanoparticle Drugs Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Liposomes Nanoparticle Drugs Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Liposomes Nanoparticle Drugs Market Size and Prospect (2021-2032)
    • 1.6.6 South America Liposomes Nanoparticle Drugs Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Liposomes Nanoparticle Drugs Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Johnson & Johnson
    • 2.1.1 Johnson & Johnson Details
    • 2.1.2 Johnson & Johnson Major Business
    • 2.1.3 Johnson & Johnson Liposomes Nanoparticle Drugs Product and Solutions
    • 2.1.4 Johnson & Johnson Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.2 Sun Pharmaceutical
    • 2.2.1 Sun Pharmaceutical Details
    • 2.2.2 Sun Pharmaceutical Major Business
    • 2.2.3 Sun Pharmaceutical Liposomes Nanoparticle Drugs Product and Solutions
    • 2.2.4 Sun Pharmaceutical Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sun Pharmaceutical Recent Developments and Future Plans
  • 2.3 CSPC
    • 2.3.1 CSPC Details
    • 2.3.2 CSPC Major Business
    • 2.3.3 CSPC Liposomes Nanoparticle Drugs Product and Solutions
    • 2.3.4 CSPC Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 CSPC Recent Developments and Future Plans
  • 2.4 Kinyond
    • 2.4.1 Kinyond Details
    • 2.4.2 Kinyond Major Business
    • 2.4.3 Kinyond Liposomes Nanoparticle Drugs Product and Solutions
    • 2.4.4 Kinyond Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Kinyond Recent Developments and Future Plans
  • 2.5 Teva
    • 2.5.1 Teva Details
    • 2.5.2 Teva Major Business
    • 2.5.3 Teva Liposomes Nanoparticle Drugs Product and Solutions
    • 2.5.4 Teva Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Teva Recent Developments and Future Plans
  • 2.6 Fudan-Zhangjiang
    • 2.6.1 Fudan-Zhangjiang Details
    • 2.6.2 Fudan-Zhangjiang Major Business
    • 2.6.3 Fudan-Zhangjiang Liposomes Nanoparticle Drugs Product and Solutions
    • 2.6.4 Fudan-Zhangjiang Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Fudan-Zhangjiang Recent Developments and Future Plans
  • 2.7 Zydus Cadila
    • 2.7.1 Zydus Cadila Details
    • 2.7.2 Zydus Cadila Major Business
    • 2.7.3 Zydus Cadila Liposomes Nanoparticle Drugs Product and Solutions
    • 2.7.4 Zydus Cadila Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Zydus Cadila Recent Developments and Future Plans
  • 2.8 TTY Biopharma
    • 2.8.1 TTY Biopharma Details
    • 2.8.2 TTY Biopharma Major Business
    • 2.8.3 TTY Biopharma Liposomes Nanoparticle Drugs Product and Solutions
    • 2.8.4 TTY Biopharma Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 TTY Biopharma Recent Developments and Future Plans
  • 2.9 Pacira
    • 2.9.1 Pacira Details
    • 2.9.2 Pacira Major Business
    • 2.9.3 Pacira Liposomes Nanoparticle Drugs Product and Solutions
    • 2.9.4 Pacira Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Pacira Recent Developments and Future Plans
  • 2.10 Luye Pharma
    • 2.10.1 Luye Pharma Details
    • 2.10.2 Luye Pharma Major Business
    • 2.10.3 Luye Pharma Liposomes Nanoparticle Drugs Product and Solutions
    • 2.10.4 Luye Pharma Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Luye Pharma Recent Developments and Future Plans
  • 2.11 Leadiant Biosciences
    • 2.11.1 Leadiant Biosciences Details
    • 2.11.2 Leadiant Biosciences Major Business
    • 2.11.3 Leadiant Biosciences Liposomes Nanoparticle Drugs Product and Solutions
    • 2.11.4 Leadiant Biosciences Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Leadiant Biosciences Recent Developments and Future Plans
  • 2.12 Ipsen
    • 2.12.1 Ipsen Details
    • 2.12.2 Ipsen Major Business
    • 2.12.3 Ipsen Liposomes Nanoparticle Drugs Product and Solutions
    • 2.12.4 Ipsen Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Ipsen Recent Developments and Future Plans
  • 2.13 Sayre Therapeutics
    • 2.13.1 Sayre Therapeutics Details
    • 2.13.2 Sayre Therapeutics Major Business
    • 2.13.3 Sayre Therapeutics Liposomes Nanoparticle Drugs Product and Solutions
    • 2.13.4 Sayre Therapeutics Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Sayre Therapeutics Recent Developments and Future Plans
  • 2.14 Jazz
    • 2.14.1 Jazz Details
    • 2.14.2 Jazz Major Business
    • 2.14.3 Jazz Liposomes Nanoparticle Drugs Product and Solutions
    • 2.14.4 Jazz Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Jazz Recent Developments and Future Plans
  • 2.15 Alnylam
    • 2.15.1 Alnylam Details
    • 2.15.2 Alnylam Major Business
    • 2.15.3 Alnylam Liposomes Nanoparticle Drugs Product and Solutions
    • 2.15.4 Alnylam Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Alnylam Recent Developments and Future Plans
  • 2.16 Bausch Health
    • 2.16.1 Bausch Health Details
    • 2.16.2 Bausch Health Major Business
    • 2.16.3 Bausch Health Liposomes Nanoparticle Drugs Product and Solutions
    • 2.16.4 Bausch Health Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Bausch Health Recent Developments and Future Plans
  • 2.17 Acrotech Biopharma
    • 2.17.1 Acrotech Biopharma Details
    • 2.17.2 Acrotech Biopharma Major Business
    • 2.17.3 Acrotech Biopharma Liposomes Nanoparticle Drugs Product and Solutions
    • 2.17.4 Acrotech Biopharma Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Acrotech Biopharma Recent Developments and Future Plans
  • 2.18 Takeda
    • 2.18.1 Takeda Details
    • 2.18.2 Takeda Major Business
    • 2.18.3 Takeda Liposomes Nanoparticle Drugs Product and Solutions
    • 2.18.4 Takeda Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Takeda Recent Developments and Future Plans
  • 2.19 Chiesi Farmaceutici
    • 2.19.1 Chiesi Farmaceutici Details
    • 2.19.2 Chiesi Farmaceutici Major Business
    • 2.19.3 Chiesi Farmaceutici Liposomes Nanoparticle Drugs Product and Solutions
    • 2.19.4 Chiesi Farmaceutici Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Chiesi Farmaceutici Recent Developments and Future Plans
  • 2.20 Gilead Sciences
    • 2.20.1 Gilead Sciences Details
    • 2.20.2 Gilead Sciences Major Business
    • 2.20.3 Gilead Sciences Liposomes Nanoparticle Drugs Product and Solutions
    • 2.20.4 Gilead Sciences Liposomes Nanoparticle Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.20.5 Gilead Sciences Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Liposomes Nanoparticle Drugs Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Liposomes Nanoparticle Drugs by Company Revenue
    • 3.2.2 Top 3 Liposomes Nanoparticle Drugs Players Market Share in 2025
    • 3.2.3 Top 6 Liposomes Nanoparticle Drugs Players Market Share in 2025
  • 3.3 Liposomes Nanoparticle Drugs Market: Overall Company Footprint Analysis
    • 3.3.1 Liposomes Nanoparticle Drugs Market: Region Footprint
    • 3.3.2 Liposomes Nanoparticle Drugs Market: Company Product Type Footprint
    • 3.3.3 Liposomes Nanoparticle Drugs Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Liposomes Nanoparticle Drugs Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Liposomes Nanoparticle Drugs Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Liposomes Nanoparticle Drugs Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Liposomes Nanoparticle Drugs Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Liposomes Nanoparticle Drugs Consumption Value by Type (2021-2032)
  • 6.2 North America Liposomes Nanoparticle Drugs Market Size by Application (2021-2032)
  • 6.3 North America Liposomes Nanoparticle Drugs Market Size by Country
    • 6.3.1 North America Liposomes Nanoparticle Drugs Consumption Value by Country (2021-2032)
    • 6.3.2 United States Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Liposomes Nanoparticle Drugs Consumption Value by Type (2021-2032)
  • 7.2 Europe Liposomes Nanoparticle Drugs Consumption Value by Application (2021-2032)
  • 7.3 Europe Liposomes Nanoparticle Drugs Market Size by Country
    • 7.3.1 Europe Liposomes Nanoparticle Drugs Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 7.3.3 France Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Liposomes Nanoparticle Drugs Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Liposomes Nanoparticle Drugs Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Liposomes Nanoparticle Drugs Market Size by Region
    • 8.3.1 Asia-Pacific Liposomes Nanoparticle Drugs Consumption Value by Region (2021-2032)
    • 8.3.2 China Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 8.3.5 India Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Liposomes Nanoparticle Drugs Consumption Value by Type (2021-2032)
  • 9.2 South America Liposomes Nanoparticle Drugs Consumption Value by Application (2021-2032)
  • 9.3 South America Liposomes Nanoparticle Drugs Market Size by Country
    • 9.3.1 South America Liposomes Nanoparticle Drugs Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Liposomes Nanoparticle Drugs Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Liposomes Nanoparticle Drugs Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Liposomes Nanoparticle Drugs Market Size by Country
    • 10.3.1 Middle East & Africa Liposomes Nanoparticle Drugs Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Liposomes Nanoparticle Drugs Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Liposomes Nanoparticle Drugs Market Drivers
  • 11.2 Liposomes Nanoparticle Drugs Market Restraints
  • 11.3 Liposomes Nanoparticle Drugs Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Liposomes Nanoparticle Drugs Industry Chain
  • 12.2 Liposomes Nanoparticle Drugs Upstream Analysis
  • 12.3 Liposomes Nanoparticle Drugs Midstream Analysis
  • 12.4 Liposomes Nanoparticle Drugs Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Liposomes Nanoparticle Drugs market size was valued at US$ 6801 million in 2025 and is forecast to a readjusted size of US$ 12960 million by 2032 with a CAGR of 9.8% during review period.
    Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
    The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market"s potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.
    This report is a detailed and comprehensive analysis for global Liposomes Nanoparticle Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Liposomes Nanoparticle Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Liposomes Nanoparticle Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Liposomes Nanoparticle Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Liposomes Nanoparticle Drugs market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Liposomes Nanoparticle Drugs
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Liposomes Nanoparticle Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Liposomes Nanoparticle Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Liposomes Drugs
    Lipid Nanoparticle Drugs
    Market segment by Application
    Hospital
    Retail Pharmacy
    Other
    Market segment by players, this report covers
    Johnson & Johnson
    Sun Pharmaceutical
    CSPC
    Kinyond
    Teva
    Fudan-Zhangjiang
    Zydus Cadila
    TTY Biopharma
    Pacira
    Luye Pharma
    Leadiant Biosciences
    Ipsen
    Sayre Therapeutics
    Jazz
    Alnylam
    Bausch Health
    Acrotech Biopharma
    Takeda
    Chiesi Farmaceutici
    Gilead Sciences
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Liposomes Nanoparticle Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Liposomes Nanoparticle Drugs, with revenue, gross margin, and global market share of Liposomes Nanoparticle Drugs from 2021 to 2026.
    Chapter 3, the Liposomes Nanoparticle Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Liposomes Nanoparticle Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Liposomes Nanoparticle Drugs.
    Chapter 13, to describe Liposomes Nanoparticle Drugs research findings and conclusion.

    Buy now